Applications of Ethynodiol Diacetate in Industrial Manufacturing

Ethynodiol diacetate serves as an essential intermediate for several regulated and specialized pharmaceutical manufacturing segments. As a high-purity synthetic progestogen, it requires precise quality control and process integration according to international standards. Our facility ensures each load meets batch-to-batch consistency and traceability, enabling customers to pursue stable formulation outcomes across diverse application channels.

1. Combined Oral Contraceptive Production

Tablet and coated pill manufacturers employ this active pharmaceutical ingredient (API) for its reliable stability in hormonal combination products. Formulators blend it with specific estrogens, balancing pharmacokinetics to ensure consistent hormone release profiles for oral contraceptives. Our supplied material supports validated production lines operating under stringent regulatory filing, as APIs must comply with multi-country dossier and product registration processes.

Industry compliance standards

• USP and Ph. Eur. monographs for Ethynodiol Diacetate
• 21 CFR Part 210/211 cGMP for pharmaceutical manufacturing
• ICH Q3A/B/C for impurity, residual solvents, and stability
• WHO Prequalification and EDQM CEP when applicable

Typical usage ratio

• 0.5–2.0 mg per tablet, as defined by registered formulation strength
• Adjustment based on clinical trial data and local regulatory authorization

Downstream process integration

• Dissolution with excipient pre-mixes in high-shear granulation
• Direct compression for final tablet core
• Coating with moisture barriers suitable for hormonal APIs
• In-process control for uniform content assay in batch finalization

Final product types

• Monophasic and multiphasic birth control tablets
• Low-dose oral contraceptives for cycle control
• Combination hormonal contraceptive packs with patient blistering

2. Progestogen-Only Hormonal Contraceptive Tablets

Specialty generics and contract manufacturers utilize ethynodiol diacetate for progestogen-only oral contraceptive tablets, especially in markets with specific health guidelines restricting estrogen use. The material provides predictable absorption in formulations requiring single-agent activity, necessitating robust impurity profiling and specialized granulation controls for hormone uniformity and dosage accuracy.

Industry compliance standards

• Pharmacopoeial standards (USP, BP, Ph. Eur.) for progestogens
• GMP Grade: ICH Q7 and FDA 21 CFR 314 (ANDA/MAA requirements)
• WHO Model List of Essential Medicines for product eligibility
• CMO QMS audits and validated cleaning protocols for hormone containment

Typical usage ratio

• 0.5–1.0 mg per tablet, subject to regionally approved indications
• Recalibration during process validation for bioequivalence demonstration

Downstream process integration

• Integration in controlled humidity rooms due to hormonal API sensitivity
• Dispensing into micro-dose feeders for small batch trials and scale-up
• Automated in-line sampling for stratified content uniformity testing
• Packaging in light-blocking blisters to maintain shelf stability

Final product types

• Daily progestogen-only contraceptive pills (POPs)
• Generic progestogen-only oral dosage forms seeking local regulatory approval
• Shelf-stable mini-pill strips for OTC and prescription channels

3. Hormone Replacement Therapy (HRT) Pharmaceutical Formulations

Pharmaceutical producers incorporate this progestin in oral hormone replacement therapies for menopausal management. Formulation teams design matrix or sequential dosing formats that address both absorption kinetics and end-product stability. Our material meets release and stability criteria for HRT tablet manufacturing, supporting robust analytical method validation and compliance with multi-country product pipelines.

Industry compliance standards

• EMA and FDA guidelines for HRT medicinal products
• Ph. Eur. and USP standardization for batch release
• EU GMP Annex 13 for clinical trial products (if used in studies)
• ICH Q1A/B for stability and shelf-life assignment

Typical usage ratio

• 0.5–1.5 mg per dose, determined by clinical regimen and local SmPC
• Ratio modified according to estrogen co-administration

Downstream process integration

• Co-processing with microcrystalline cellulose or starch for release control
• Accurate feeding into multi-station tableting equipment for phase-dosing packs
• Immediate post-tableting quality checks for hormone content
• Sequential packaging to separate progestin and estrogen phases

Final product types

• Combined estrogen-progestogen tablets for menopause symptom control
• Sequential HRT packs for cyclic therapy approaches
• Generic and branded HRT formulations

4. Research & Development of Next-Generation Hormonal APIs

Drug discovery and analytics laboratories order certified batches for stability, pharmacokinetic, and method validation studies targeting upgrades of oral hormonal APIs. These projects rely on consistent impurity profiles and high lot traceability to comply with regulatory filing requirements for investigational use and generic API registration. Custom specifications and tailored documentation support rapid product development efforts.

Industry compliance standards

• GLP (Good Laboratory Practice) and OECD Guidelines for R&D studies
• Documentation conforming to ICH M7 for mutagenic impurity risk
• Custom Certificate of Analysis (CoA) and full spectral data files
• Chain of Custody tracking for reference standard shipments

Typical usage ratio

• 10 mg to 5 g per batch, depending on research phase or pilot study scale
• Adjustable sample sizes based on analytical throughput and protocol demand

Downstream process integration

• Solubilization for HPLC and LC-MS quantification in stability chambers
• Dosing for in-vivo PK studies or in-vitro dissolution tests
• Blending into trial tablet cores for dissolution and stress testing
• Archiving excess material for long-term batch comparison

Final product types

• Reference standards for analytical validation
• Clinical trial supplies for FIH (first-in-human) or BE (bioequivalence) studies
• Small-scale pilot tablet runs for regulatory submission packs